SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network

Rare disease patients may suffer delayed access to new drugs as SARS-CoV-2 is disrupting clinical trials. This survey demonstrates that the European Cystic Fibrosis Clinical Trials Network is ideally placed to track and address such disruption. https://bit.ly/3hCw5dq

Detalles Bibliográficos
Autores principales: van Koningsbruggen-Rietschel, Silke, Dunlevy, Fiona, Bulteel, Veerle, Downey, Damian G., Dupont, Lieven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411273/
https://www.ncbi.nlm.nih.gov/pubmed/32764115
http://dx.doi.org/10.1183/13993003.02114-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411273/
https://www.ncbi.nlm.nih.gov/pubmed/32764115
http://dx.doi.org/10.1183/13993003.02114-2020

Ejemplares similares